{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:35:50Z","timestamp":1785774950317,"version":"3.56.0"},"reference-count":37,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Data on disease control, treatment, and quality of life (QoL) in patients with psoriasis from Baltic countries are lacking. In this study, we aimed to assess the disease control, treatment, and QoL of patients with psoriasis in countries from Central and Eastern Europe, and we report data for the Baltic countries. Materials and Methods: In a cross-sectional, international study (CRYSTAL), we retrospectively assessed the real-world disease severity and QoL in adult patients (18\u201375 years) from Estonia, Latvia, and Lithuania with moderate-to-severe psoriasis receiving continuous systemic treatment \u2265 24 weeks. Analyses included 50 patients from each country and were descriptive. Results: The median disease duration was 15.2\u201319.9 years across the countries. Most patients (78.0% in Estonia, 100% in Latvia, and 68.0% in Lithuania) were receiving monotherapy with biological agents, mainly TNF inhibitors. An absolute PASI score \u2264 3 was achieved by 82.0%, 70.0%, and 64.0% of patients in the overall study population and 89.7%, 70.0%, and 61.8% of patients receiving biologic monotherapy in Estonia, Latvia, and Lithuania, respectively. Across the countries, impairments in QoL as expressed by a Dermatology Life Quality Index score &gt; 5 were reported by 14.0\u201334.0% of patients, while 88.0\u201396.0% of patients were satisfied with their treatment. Conclusions: Although most patients showed low absolute PASI scores and satisfaction with their evolution after \u226524 weeks of systemic treatment, they still reported an impact on QoL. This finding underlines that further optimization of systemic treatment strategies is needed to improve outcomes in moderate-to-severe psoriasis in Baltic countries.<\/jats:p>","DOI":"10.3390\/medicina61030397","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:13:18Z","timestamp":1740463998000},"page":"397","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study"],"prefix":"10.3390","volume":"61","author":[{"given":"Maigi","family":"Eisen","sequence":"first","affiliation":[{"name":"Center of Dermatology and Venereology, The North Estonia Medical Centre, 13419 Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Hartmane","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Faculty of Medicine, Riga Stradins University, LV-1010 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fclli","family":"Kingo","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University of Tartu, 50090 Tartu, Estonia"},{"name":"Dermatology Clinic, Tartu University Hospital, 50417 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmars","family":"Mikazans","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Faculty of Medicine, Riga Stradins University, LV-1010 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Toomson","sequence":"additional","affiliation":[{"name":"Department of Dermatovenerology, P\u00e4rnu Central Hospital, 80010 P\u00e4rnu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Toomela","sequence":"additional","affiliation":[{"name":"AbbVie, 10145 Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skaidra","family":"Valiukeviciene","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases, Medical Academy, Lithuanian University of Health Sciences (LUHS), LT-44307 Kaunas, Lithuania"},{"name":"Department of Skin and Venereal Diseases, Hospital of LUHS Kauno Klinikos, LT-50161 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/jdv.18050","article-title":"Prevalence of most common skin diseases in Europe: A population-based study","volume":"36","author":"Richard","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1684\/ejd.2022.4245","article-title":"Global trends in the incidence of psoriasis from 1990 to 2019","volume":"32","author":"Mou","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Damiani, G., Bragazzi, N.L., Karimkhani Aksut, C., Wu, D., Alicandro, G., McGonagle, D., Guo, C., Dellavalle, R., Grada, A., and Wong, P. (2021). The global, regional, and national burden of psoriasis: Results and insights from the Global Burden of Disease 2019 Study. Front. Med., 8.","DOI":"10.3389\/fmed.2021.743180"},{"key":"ref_5","first-page":"173","article-title":"Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: Results from National Psoriasis Foundation panel surveys","volume":"95","author":"Zhu","year":"2015","journal-title":"Cutis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/jdv.12572","article-title":"Impact of psoriasis severity on family income and quality of life","volume":"29","author":"Hawro","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14737167.2014.933671","article-title":"The economic burden of psoriasis: A systematic literature review","volume":"14","author":"Feldman","year":"2014","journal-title":"Expert. Rev. Pharmacoecon Outcomes Res."},{"key":"ref_8","first-page":"874","article-title":"Economic and comorbidity burden among patients with moderate-to-severe psoriasis","volume":"21","author":"Feldman","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_9","unstructured":"Global Psoriasis Atlas (2024, October 15). National, Regional and Worldwide Estimates of the Epidemiology of Psoriasis. Available online: https:\/\/globalpsoriasisatlas.org\/en\/explore\/prevalence-heatmap."},{"key":"ref_10","first-page":"158","article-title":"Immunopathogenic treatment options for psoriasis patients under a restrictive reimbursement environment","volume":"75","author":"Hartmane","year":"2021","journal-title":"Proc. Latv. Acad. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_13","first-page":"Cd011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","article-title":"The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients","volume":"28","author":"Abrouk","year":"2017","journal-title":"J. Dermatolog. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","article-title":"Redefining the therapeutic objective in psoriatic patients candidates for biological therapy","volume":"29","author":"Carretero","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: Defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e15166","DOI":"10.1111\/dth.15166","article-title":"Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study","volume":"35","author":"Colombo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","article-title":"Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort","volume":"102","author":"Thomas","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dth.12267","article-title":"An evolution in switching therapy for psoriasis patients who fail to meet treatment goals","volume":"28","author":"Kerdel","year":"2015","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000345715","article-title":"Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice","volume":"225","author":"Norlin","year":"2012","journal-title":"Dermatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/jdv.13222","article-title":"Use of biologics for psoriasis in Central and Eastern European countries","volume":"29","author":"Rencz","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/jdv.13634","article-title":"Psoriasis registries worldwide: Systematic overview on registry publications","volume":"30","author":"Eissing","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Raam, L., Hartmane, I., Valiukevi\u010dien\u0117, S., Karamova, A.E., Telegdy, E., Botev, I., Marina, D., Rubant, S., Albuquerque, T., and Constantin, M.M. (2024). Disease severity, treatment patterns and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: Results of the CRYSTAL observational study in Central and Eastern European countries. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1410540"},{"key":"ref_25","first-page":"151","article-title":"A survey of disease severity, quality of life, and treatment patterns of biologically naive patients with psoriasis in central and eastern Europe","volume":"18","author":"Palota","year":"2010","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_28","unstructured":"Statistics Estonia (2024, October 15). Population Figure. Available online: http:\/\/www.stat.ee\/en\/find-statistics\/statistics-theme\/population\/population-figure."},{"key":"ref_29","unstructured":"Official Statistics Portal\u2014Official Statistics of Latvia (2024, October 15). Population and Population Change, Available online: https:\/\/stat.gov.lv\/en\/statistics-themes\/population\/population\/247-population-and-population-change?themeCode=IR."},{"key":"ref_30","unstructured":"Official Statistics Portal (2024, October 15). Population of Lithuania (Edition 2020), Available online: http:\/\/osp.stat.gov.lt\/en\/lietuvos-gyventojai-2020\/salies-gyventojai\/gyventoju-skaicius-ir-sudetis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/07853890.2021.1986637","article-title":"Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: An experts opinion document","volume":"53","author":"Dauden","year":"2021","journal-title":"Ann. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.12562","article-title":"Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review","volume":"28","author":"Rouzaud","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.medici.2016.07.001","article-title":"Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis","volume":"52","year":"2016","journal-title":"Medicina"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Raudonis, T., Gliebute, A., Grigaityte, A.G., Lukosiunaite, Z., Karmaziene, T., and Grigaitiene, J. (2020). A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology. Medicina, 56.","DOI":"10.3390\/medicina56060275"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2013.1083","article-title":"Standardizing training for psoriasis measures: Effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_37","unstructured":"Reilly Associates (2024, October 15). Work Productivity and Activity Impairment Questionnaire (WPAI) Scoring. Available online: http:\/\/www.reillyassociates.net\/."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:02Z","timestamp":1760028122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["medicina61030397"],"URL":"https:\/\/doi.org\/10.3390\/medicina61030397","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}